“…While the trials are all intended to expand on Z0011 and include patients treated with both BCT and mastectomy, they have slightly different inclusion/exclusion criteria, interventions, primary outcomes, adjuvant radiation protocols, and use of ultrasound to screen the axilla. [7][8][9][10][11] The diversity of the trials offers a more comprehensive path forward at the risk of obfuscation in the case of contradictory results. Regardless, these trials should offer level I evidence on the omission of cALND after mastectomy and may offer secondary results on clinical outcomes between BCT and mastectomy.…”